![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GLY-200 is a first-in-class, orally administered, non-absorbed polymeric drug that was designed to target and enhance the natural mucus barrier of the duodenum. It is being evaluated for Obesity.
Lead Product(s): GLY-200
Therapeutic Area: Nutrition and Weight Loss Product Name: GLY-200
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2024
Details:
GLY-200 is an oral, proprietary mucin-complexing polymer and first and only clinical-stage, potentially disease-modifying, pharmacologic polymer therapy in clinical development for the treatment of type 2 diabetes and obesity.
Lead Product(s): GLY-200
Therapeutic Area: Endocrinology Product Name: GLY-200
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Glyscend reported key results from the study indicating that 5-days dosing with GLY-200 resulted in statistically significant effects on glucose, insulin, and bile acids, and was associated with changes in gut hormones such as GLP-1 and glicentin compared to placebo.
Lead Product(s): GLY-200
Therapeutic Area: Endocrinology Product Name: GLY-200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022